MX2022015488A - Tratamiento para la disfuncion auricular. - Google Patents

Tratamiento para la disfuncion auricular.

Info

Publication number
MX2022015488A
MX2022015488A MX2022015488A MX2022015488A MX2022015488A MX 2022015488 A MX2022015488 A MX 2022015488A MX 2022015488 A MX2022015488 A MX 2022015488A MX 2022015488 A MX2022015488 A MX 2022015488A MX 2022015488 A MX2022015488 A MX 2022015488A
Authority
MX
Mexico
Prior art keywords
treatment
atrial dysfunction
atrial
dysfunction
patient
Prior art date
Application number
MX2022015488A
Other languages
English (en)
Spanish (es)
Inventor
Jean-Francois Tamby
Chun Yang
Jay M Edelberg
Marcus Patrick Henze
Gregory Howard Takeo Kurio
Cynthia Lyle Kelly
Rio Carlos L Del
Robert Lee Anderson
Marius P Sumandea
Jitendra Ganju
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of MX2022015488A publication Critical patent/MX2022015488A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
MX2022015488A 2020-06-15 2021-06-14 Tratamiento para la disfuncion auricular. MX2022015488A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063039438P 2020-06-15 2020-06-15
US202063042512P 2020-06-22 2020-06-22
PCT/US2021/037230 WO2021257456A1 (en) 2020-06-15 2021-06-14 Treatment of atrial dysfunction

Publications (1)

Publication Number Publication Date
MX2022015488A true MX2022015488A (es) 2023-03-21

Family

ID=76845320

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015488A MX2022015488A (es) 2020-06-15 2021-06-14 Tratamiento para la disfuncion auricular.

Country Status (13)

Country Link
US (1) US20230233545A1 (enExample)
EP (1) EP4164644A1 (enExample)
JP (2) JP7832128B2 (enExample)
KR (1) KR20230024977A (enExample)
CN (1) CN116056703A (enExample)
AU (1) AU2021293817A1 (enExample)
BR (1) BR112022025551A2 (enExample)
CA (1) CA3180943A1 (enExample)
CL (1) CL2022003548A1 (enExample)
IL (1) IL298885A (enExample)
MX (1) MX2022015488A (enExample)
TW (1) TW202214241A (enExample)
WO (1) WO2021257456A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759640B2 (en) * 2022-01-07 2023-09-19 Xyra, Llc Methods for reducing the risk of strokes by pharmacotherapy to reduce the number and duration of atrial fibrillations
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途
CN119157623A (zh) * 2023-12-12 2024-12-20 成都迈格因科技有限公司 一种经导管心脏射频消融的蒸汽爆破安全预警和控制系统
CN117815534A (zh) * 2023-12-12 2024-04-05 苏州晟智医疗科技有限公司 反搏辅助装置、计算设备、存储介质及反搏系统
CN118304374A (zh) * 2024-04-01 2024-07-09 山东省中医药研究院附属医院 一种组合物在制备治疗心动过速和/或瓣膜反流药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021553074A1 (en) * 2015-01-22 2023-03-06 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
US10758525B2 (en) * 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
JP2020519628A (ja) * 2017-05-10 2020-07-02 インカーダ セラピューティクス， インコーポレイテッド 肺投与によって心臓の状態を処置するための単位用量、エアロゾル、キットおよび方法
LT3645002T (lt) * 2017-06-30 2025-02-10 Amgen Inc. Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais
CA3138080A1 (en) * 2019-05-19 2020-11-26 Jean-Francois TAMBY Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl) n-(isoxazol-3-yl)piperidine-1-carboxamid

Also Published As

Publication number Publication date
BR112022025551A2 (pt) 2023-03-07
CA3180943A1 (en) 2021-12-23
EP4164644A1 (en) 2023-04-19
AU2021293817A1 (en) 2023-01-19
JP7832128B2 (ja) 2026-03-17
CN116056703A (zh) 2023-05-02
CL2022003548A1 (es) 2023-06-09
US20230233545A1 (en) 2023-07-27
IL298885A (en) 2023-02-01
KR20230024977A (ko) 2023-02-21
WO2021257456A1 (en) 2021-12-23
JP2026048841A (ja) 2026-03-17
TW202214241A (zh) 2022-04-16
JP2023529502A (ja) 2023-07-10

Similar Documents

Publication Publication Date Title
CL2021003045A1 (es) Tratamiento de la disfunción sistólica
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12020551427A1 (en) Epinephrine spray formulations
CL2021002669A1 (es) (divisional de solicitud 3443-2018) tratamientos de cancer.
CL2022003548A1 (es) Tratamiento de la disfunción auricular
BR112021020247A2 (pt) Composições e métodos para melhorar a saúde da pele e para o tratamento e prevenção de doenças, distúrbios e afecções associadas a micróbios patogênicos
MX2020000713A (es) Metodos de aferesis y sus usos.
MX2020011016A (es) Composiciones para el tratamiento de condiciones de la piel.
EP4316501A3 (en) Botanical and bacterial extracts displaying retinol-like activity
MX2025002953A (es) Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis
WO2008017025A3 (en) Combination therapy
MX2023012095A (es) Inhibidores de hdac6 para el uso en el tratamiento de la miocardiopatía dilatada.
MX2021014905A (es) Células seguras e invisibles para el sistema inmunitario.
MX2022009384A (es) Usos terapeuticos de la tirzepatida.
MX2014000567A (es) Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios.
MX2017009963A (es) Composición y método para el tratamiento de padecimientos de la piel.
MX2020006005A (es) Copolimeros bloque anfifilicos, micelas y metodos para tratar o prevenir insuficiencia cardiaca.
MX2021006933A (es) Administración de sulcardina para el tratamiento de fibrilación auricular aguda.
MX2025004900A (es) Tratamiento de verrugas
WO2020231237A3 (ko) 위치고정튜브를 구비한 삼첨판막 역류증 시술용 기구
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
ZA202207601B (en) Treatment of acute heart failure
MX2023004881A (es) Inhibidores de pde9 para el tratamiento de insuficiencia cardíaca.
MX2020000118A (es) Composiciones y metodos para mejorar la funcion cardiaca.
WO2019027299A3 (ko) 간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학 조성물